<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="34f532a1-4ea5-4a4e-e063-6294a90a0c10"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS.
 <br/>
      <br/>
POTASSIUM CHLORIDE extended-release tablets, for oral use
 <br/>
Initial U.S. Approval: 1948
</title>
   <effectiveTime value="20250512"/>
   <setId root="c2028705-9e5b-424b-983a-1c7a71dedd74"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="156893695"/>
            <name>PD-Rx Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="156893695"/>
                  <name>PD-Rx Pharmaceuticals, Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="156893695"/>
                        <name>PD-Rx Pharmaceuticals, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72789-503" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="34f53aba-dda1-5579-e063-6294a90a1056"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250512"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72789-503" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Potassium chloride</name>
                        <formCode code="C42930" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Potassium Chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="72888-075" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="I9O0E3H2ZE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PARAFFIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="32K497ZK2U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="750"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM CHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72789-503-95" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250512"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA215725" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220725"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>White to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">UpArrowhead;111</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="34f532a1-4ea6-4a4e-e063-6294a90a0c10"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Potassium chloride extended-release tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.</paragraph>
               </text>
               <effectiveTime value="20240913"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Potassium chloride extended-release tablets are potassium salt indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
 
    <linkHtml href="#S1">(1)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="34f532a1-4ea7-4a4e-e063-6294a90a0c10"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20210106"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Monitor serum potassium and adjust dosages accordingly
  
     <linkHtml href="#S2.1">(2.1)</linkHtml>
                           </item>
                           <item>If serum potassium concentration is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation
  
     <linkHtml href="#S2.1">(2.1)</linkHtml>
                           </item>
                           <item>Take with meals and with a glass of water or other liquid. Swallow tablets whole.
  
     <linkHtml href="#S2.1">(2.1)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Treatment of hypokalemia:</content>Typical dose range is 40-100 mEq per day in divided doses. Limit doses to 20 mEq per dose.
  
     <linkHtml href="#S2.2">(2.2)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Prevention of hypokalemia:</content>Typical dose is 20 mEq per day
  
     <linkHtml href="#S2.2">(2.2)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="34f532a1-4ea8-4a4e-e063-6294a90a0c10"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.1 Monitoring and Administration</title>
                     <text>
                        <paragraph>If serum potassium concentration is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Monitoring</content>
                        </paragraph>
                        <paragraph>Monitor serum potassium and adjust the dose based on serum potassium level. Monitor serum potassium periodically during maintenance therapy to ensure potassium remains in desired range.</paragraph>
                        <paragraph>The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis, requires careful attention to acid-base balance, volume status, electrolytes, including magnesium, sodium, chloride, phosphate, and calcium, electrocardiograms, and the clinical status of the patient. Correct volume status, acid-base balance, and electrolyte deficits as appropriate.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Administration</content>
                        </paragraph>
                        <paragraph>Take potassium chloride extended-release tablets with meals and with a glass of water or other liquid. Do not take on an empty stomach because of its potential for gastric irritation
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#S5.1">5.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>Swallow tablets whole without crushing, chewing or sucking.</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="34f532a1-4ea9-4a4e-e063-6294a90a0c10"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.2 Dosing</title>
                     <text>
                        <paragraph>Dosage must be adjusted to the individual needs of each patient. Dosages greater than 20 mEq per day should be divided such that no more than 20 mEq is given in a single dose.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Treatment of hypokalemia:</content>Typical dose range is 40-100 mEq per day.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Prevention of hypokalemia:</content>Typical dose is 20 mEq per day.

 </paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="34f532a1-4eaa-4a4e-e063-6294a90a0c10"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>10 mEq (750mg) : White to off-white, film coated, capsule shaped tablet, debossed with “111” on one side and” Λ” on other side.</item>
                     <item>15 mEq (1125 mg): Yellow colored, Film coated, Capsule shaped tablet, debossed with “E41” on one side and “Λ” on other side.</item>
                     <item>20 mEq (1500 mg): White to off-white, film coated, capsule shaped tablet, debossed with “112” on one side and” Λ” on other side.</item>
                  </list>
               </text>
               <effectiveTime value="20210106"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>10 mEq (750mg) oral tablets
  
     <linkHtml href="#S3">(3)</linkHtml>
                           </item>
                           <item>15 mEq (1125 mg) oral tablet
  
     <linkHtml href="#S3">(3)</linkHtml>
                           </item>
                           <item>20 mEq (1500 mg) oral tablets
  
     <linkHtml href="#S3">(3)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="34f532a1-4eab-4a4e-e063-6294a90a0c10"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Potassium chloride is contraindicated in patients on triamterene or amiloride.</paragraph>
               </text>
               <effectiveTime value="20210106"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Concomitant use with triamterene and amiloride
  
     <linkHtml href="#S4">(4</linkHtml>,
  
     <linkHtml href="#S7.1">7.1)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="34f532a1-4eac-4a4e-e063-6294a90a0c10"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20210106"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Gastrointestinal Adverse Reactions: Can produce ulcerative and/or stenotic lesions of the gastrointestinal tract, particularly when in prolonged contact with the gastrointestinal mucosa. Take with meals.
  
     <linkHtml href="#S5.1">(5.1)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="34f532a1-4ead-4a4e-e063-6294a90a0c10"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.1 Gastrointestinal Adverse Reactions</title>
                     <text>
                        <paragraph>Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract, particularly when the drug remains in contact with the gastrointestinal mucosa for a prolonged period of time. Consider the use of liquid potassium in patients with dysphagia, swallowing disorders, or severe gastrointestinal motility disorders.</paragraph>
                        <paragraph>If severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs, discontinue potassium chloride extended-release tablets and consider possibility of ulceration, obstruction or perforation.</paragraph>
                        <paragraph>Potassium chloride extended-release tablets should not be taken on an empty stomach because of its potential for gastric irritation
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#S2.1">2.1</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="34f532a1-4eae-4a4e-e063-6294a90a0c10"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions have been identified with use of oral potassium salts. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea.</paragraph>
                  <paragraph>There have been reports of hyperkalemia and of upper and lower gastrointestinal conditions including obstruction, bleeding, ulceration, perforation
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#S5.1">5.1</linkHtml>) and Overdosage (
  
   <linkHtml href="#S10">10</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>Skin rash has been reported rarely.</paragraph>
               </text>
               <effectiveTime value="20210106"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea
 
    <linkHtml href="#S6">(6)</linkHtml>
                        </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Advagen Pharma Ltd, at 866-488-0312 or FDA at 1-800-FDA-1088 or
  
     <linkHtml href="www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.
 
    </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="34f532a1-4eaf-4a4e-e063-6294a90a0c10"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20210106"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Renin-angiotensin-aldosterone system inhibitors: Monitor for hyperkalemia
  
     <linkHtml href="#S7.2">(7.2)</linkHtml>
                           </item>
                           <item>Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia
  
     <linkHtml href="#S7.3">(7.3)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="34f532a1-4eb0-4a4e-e063-6294a90a0c10"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>7.1 Triamterene and Amiloride</title>
                     <text>
                        <paragraph ID="p463711291507905762">Use with triamterene or amiloride can produce severe hyperkalemia. Avoid concomitant use
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#S4">4</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="34f532a1-4eb1-4a4e-e063-6294a90a0c10"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.2 Renin-Angiotensin-Aldosterone System Inhibitors</title>
                     <text>
                        <paragraph ID="p46106291507905883">Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy.</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="34f532a1-4eb2-4a4e-e063-6294a90a0c10"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.3 Nonsteroidal Anti-Inflammatory Drugs</title>
                     <text>
                        <paragraph>Nonsteroidal anti-inflammatory drugs (NSAIDs) may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients receiving concomitant NSAID therapy.</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="34f532a1-4eb3-4a4e-e063-6294a90a0c10"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250110"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Cirrhosis: Initiate therapy at the low end of the dosing range
  
     <linkHtml href="#S8.6">(8.6)</linkHtml>
                           </item>
                           <item>Renal Impairment: Initiate therapy at the low end of the dosing range
  
     <linkHtml href="#S8.7">(8.7)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="34f532a1-4eb4-4a4e-e063-6294a90a0c10"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm.</paragraph>
                        <paragraph>The background risk for major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="34f532a1-4eb5-4a4e-e063-6294a90a0c10"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>The normal potassium ion content of human milk is about 13 mEq per liter. Since potassium from oral supplements such as potassium chloride becomes part of the body potassium pool, as long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk.</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="34f532a1-4eb6-4a4e-e063-6294a90a0c10"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of potassium chloride extended-release tablets in children have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="34f532a1-4eb7-4a4e-e063-6294a90a0c10"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of potassium chloride extended-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="34f532a1-4eb8-4a4e-e063-6294a90a0c10"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.6 Cirrhotics</title>
                     <text>
                        <paragraph>Doses of potassium in patients with cirrhosis produce a larger increase in potassium levels compared to the response in normal patients. Based on published literature, the baseline corrected serum concentrations of potassium measured over 3 hours after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load. Patients with cirrhosis should usually be started at the low end of the dosing range, and the serum potassium level should be monitored frequently.</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="34f532a1-4eb9-4a4e-e063-6294a90a0c10"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph>Patients with renal impairment have reduced urinary excretion of potassium and are at substantially increased risk of hyperkalemia. Patients with impaired renal function, particularly if the patient is on RAAS inhibitors or NSAIDs, should usually be started at the low end of the dosing range because of the potential for development of hyperkalemia
 
  <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#S7.2">7.2</linkHtml>,
  
   <linkHtml href="#S7.3">7.3</linkHtml>)]
 
  </content>. The serum potassium level should be monitored frequently. Renal function should be assessed periodically.

 </paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="34f532a1-4eba-4a4e-e063-6294a90a0c10"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20210106"/>
               <component>
                  <section ID="S10.1">
                     <id root="34f532a1-4ebb-4a4e-e063-6294a90a0c10"/>
                     <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
                     <title>10.1 Symptoms</title>
                     <text>
                        <paragraph>The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, potentially fatal hyperkalemia can result
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#S4">4</linkHtml>)
 
  </content>and
 
  <content styleCode="italics">Warnings and Precautions (
  
   <linkHtml href="#S5.1">5.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>Hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss P-waves, depression of S-T segments, and prolongation of the QT intervals). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
               <component>
                  <section ID="S10.2">
                     <id root="34f532a1-4ebc-4a4e-e063-6294a90a0c10"/>
                     <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
                     <title>10.2 Treatment</title>
                     <text>
                        <paragraph>Treatment measures for hyperkalemia include the following:</paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>Monitor closely for arrhythmias and electrolyte changes.</item>
                           <item>Eliminate foods and medications containing potassium and of any agents with potassium sparing properties such as potassium-sparing diuretics, ARBs, ACE inhibitors, NSAIDs, certain nutritional supplements, and many others.</item>
                           <item>Administer intravenous calcium gluconate if the patient is at no risk or low risk of developing digitalis toxicity.</item>
                           <item>Administer intravenously 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1,000 mL.</item>
                           <item>Correct acidosis, if present, with intravenous sodium bicarbonate.</item>
                           <item>Use exchange resins, hemodialysis, or peritoneal dialysis.</item>
                        </list>
                        <paragraph>In patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity.</paragraph>
                        <paragraph>The extended release feature means that absorption and toxic effects may be delayed for hours. Consider standard measures to remove any unabsorbed drug.</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="34f532a1-4ebd-4a4e-e063-6294a90a0c10"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Potassium chloride extended-release tablets are a solid oral dosage form of potassium chloride containing 750 mg, 1125 mg and 1500 mg of potassium chloride, USP, equivalent to 10 mEq, 15 mEq and 20 mEq of potassium, respectively, in a film-coated matrix tablet.</paragraph>
                  <paragraph>The chemical name is potassium chloride, and the structural formula is KCl. Potassium chloride, USP, occurs as a white, granular powder or as colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol.</paragraph>
                  <paragraph>The 10 mEq, 15 mEq and 20 mEq tablets contain colloidal silicon dioxide, magnesium stearate, paraffin, polyethylene glycol, polyvinyl acetate, povidone, sodium lauryl sulphate, polyvinyl alcohol, talc, titanium dioxide, triethyl citrate, D&amp;C yellow # 10 (for 15 mEq) and FD&amp;C yellow # 6 (for 15 mEq).</paragraph>
                  <paragraph>FDA approved dissolution test specifications and assay sample preparation method differs from USP.</paragraph>
               </text>
               <effectiveTime value="20210831"/>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="34f532a1-4ebe-4a4e-e063-6294a90a0c10"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20210106"/>
               <component>
                  <section ID="S12.1">
                     <id root="34f532a1-4ebf-4a4e-e063-6294a90a0c10"/>
                     <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The potassium ion (K
 
  <sup>+</sup>) is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulse; the contraction of cardiac, skeletal and smooth muscle; and the maintenance of normal renal function.

 </paragraph>
                        <paragraph>The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane.</paragraph>
                        <paragraph>Potassium is a normal dietary constituent, and under steady state conditions, the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day.</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="34f532a1-4ec0-4a4e-e063-6294a90a0c10"/>
                     <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
                     <title>12.2 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cirrhotics</content>
                        </paragraph>
                        <paragraph>Based on published literature, the baseline corrected serum concentrations of potassium measured over 3 hours after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#S8.6">8.6</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="34f532a1-4ec1-4a4e-e063-6294a90a0c10"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20210106"/>
               <component>
                  <section ID="S13.1">
                     <id root="34f532a1-4ec2-4a4e-e063-6294a90a0c10"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Carcinogenicity, mutagenicity and fertility studies in animals have not been performed. Potassium is a normal dietary constituent.</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="34f53997-9caf-4eee-e063-6294a90a5cd8"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Potassium chloride extended-release tablets, USP contain 750 mg of potassium chloride (equivalent to 10 mEq of potassium, respectively). Potassium chloride extended-release tablets are provided as film coated tablets in following strengths and package configurations:</paragraph>
                  <table cellspacing="0">
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule">
                              <paragraph>
                                 <content styleCode="bold">Strength</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule">
                              <paragraph>
                                 <content styleCode="bold">Description</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule">
                              <paragraph>
                                 <content styleCode="bold">Bottle Count</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule">
                              <paragraph>
                                 <content styleCode="bold">NDC #</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="3" styleCode="Rrule Lrule Botrule">
                              <paragraph>10 mEq
      <br/>
			(750 mg)
     </paragraph>
                           </td>
                           <td rowspan="3" styleCode="Rrule Lrule Botrule">
                              <paragraph>White to off-white, film coated, capsule shaped tablet, debossed with “111” on one side and” Λ” on other side</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule">
                              <paragraph>1000</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule">
                              <paragraph>72789-503-95</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="italics">Recommended Storage</content>
                  </paragraph>
                  <paragraph>Store at room temperature 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20210831"/>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="34f532a1-4ec4-4a4e-e063-6294a90a0c10"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Inform patients to take each dose with meals and with a full glass of water or other liquid, and to not crush, chew, or suck the tablets.</item>
                     <item>Advise patients to seek medical attention if tarry stools or other evidence of gastrointestinal bleeding is noticed.</item>
                     <item>Inform patients that the wax tablet is not absorbed and may be excreted intact in the stool. If the patient observes this, it is not an indication of lack of effect.</item>
                  </list>
                  <paragraph>All the brands are trademarks of their respective owners.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed By:</content>
                     <br/>  Advagen Pharma Ltd., 
  <br/>  East Windsor, NJ 08520, USA.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                     <br/>  Rubicon Research Pvt. Ltd., 
  <br/>  Thane, 421506 India. 
  <br/>
                     <br/>  Rev. 01/2025

 </paragraph>
               </text>
               <effectiveTime value="20210106"/>
            </section>
         </component>
         <component>
            <section ID="S18">
               <id root="34f532a1-4ec5-4a4e-e063-6294a90a0c10"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Potassium chloride extended-release tablets, USP 750mg label</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
               </text>
               <effectiveTime value="20210831"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>72789503 Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="72789503.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>